551 Five-year treatment with high-dose UDCA in PSC

Olsson, Rolf; Boberg, K.M.; Muckadel, O. Schaffalitzky de; Lindgren, Stefan; Hultcrantz, Rolf; Folvik, Geir; Bell, H.; Kristiansen, G.; Matre, Jon; Rydning, Andreas; Wikman, Ola; Danielsson, Å; Sandberg-Gertzén, Hanna; Ung, Kjell-Arne; Eriksson, Anders; Lööf, Lars; Prytz, Hanne; Broomé, Ulrika

doi:10.1016/s0168-8278(04)90551-x

Cited by 8 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were confirmed by an open study from the Mayo Clinic, which showed a significant improvement in projected survival using the Mayo Risk Score in patients treated with high dose but not conventional doses of UDCA [50]. A recent trial by Olsson et al [51] also found a trend toward improved survival in the patients treated with UDCA at a dose of 17 to 23 mg/kg.…”

Section: Ursodeoxycholic Acidmentioning

confidence: 72%

Primary sclerosing cholangitis: Diagnosis and management

Charatcharoenwitthaya¹,

Lindor

2006

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease caused by progressive inflammatory destruction of intrahepatic and extrahepatic bile ducts, and ultimately cirrhosis. PSC occurs primarily in patients with underlying ulcerative colitis and affects primarily young to middle-aged men. PSC is believed to be an autoimmune disease mediated by immune dysregulation in patients with genetic susceptibility. One possible mechanism for the development of PSC is the homing of memory lymphocytes to the biliary tract. Cholangiography is the gold standard for diagnosis of PSC. The typical radiologic findings include multifocal strictures and dilation involving the intrahepatic or extrahepatic biliary tract, or both. Although no medical therapy has proved beneficial, a variety of agents have been tested, some of which appear promising and deserve further study. High-dose ursodeoxycholic acid may have benefit in slowing disease progression; a multicenter placebo-controlled trial is ongoing. Liver transplantation is a good option for patients with advanced PSC, although the disease can recur after successful transplantation.

show abstract

Section: Ursodeoxycholic Acidmentioning

confidence: 72%

Primary sclerosing cholangitis: Diagnosis and management

Charatcharoenwitthaya¹,

Lindor

2006

Curr Gastroenterol Rep

View full text Add to dashboard Cite

show abstract

“…has so far been published in abstract form only. This found a trend towards improved survival in the UDCA‐treated group but was insufficiently powered to produce a result of statistical significance 62 …”

Section: Disease Modifying Treatmentmentioning

confidence: 96%

Review article: current management of primary sclerosing cholangitis

Cullen

Chapman

2005

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary The management of primary sclerosing cholangitis (PSC) is hindered by incomplete understanding of the pathogenesis of the disease and the lack of good prognostic models. Few large randomized controlled trials of drug therapy have been published. Best practice in the management of PSC is currently based therefore on careful interpretation of the available evidence, close observation of individual patients and clinical experience of the disease. Drug therapy is useful for alleviating symptoms. Ursodeoxycholic acid may slow progression of the disease and reduce the frequency of complications. Consensus is emerging on the issues of screening for the malignant complications of PSC and the indications for liver transplantation are becoming broader and encompassing the earliest stages of cholangiocarcinoma. In view of the rarity of the disease in the general population, large international collaborations to study PSC are necessary to provide clearer answers in areas of uncertainty, and these are now beginning to emerge.

show abstract

“…The most current UDCA trial was conducted by Olsson et al (2004) with PSC patients (n = 110) using a dose of 17 to 23 mg/kg per day for 5 years. The results demonstrated a trend toward increased survival in the UDCA-treated group as compared with placebo.…”

Section: Medical Managementmentioning

confidence: 99%

Primary Sclerosing Cholangitis

Geonzon-Gonzales¹

2008

Gastroenterology Nursing

View full text Add to dashboard Cite

551 Five-year treatment with high-dose UDCA in PSC

Cited by 8 publications

References 0 publications

Primary sclerosing cholangitis: Diagnosis and management

Primary sclerosing cholangitis: Diagnosis and management

Review article: current management of primary sclerosing cholangitis

Primary Sclerosing Cholangitis

Contact Info

Product

Resources

About